Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/77082COMPARTIR / EXPORTAR:
 SHARE
 CORE
BASE
|
|
| Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
| Título: | IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer |
Autor: | Cortés-Sempere, María CSIC; Castro Carpeño, Javier de; Nistal, Manuel; Belda-Iniesta, Cristobal; Perona Abellón, Rosario CSIC ORCID; Ibáñez de Cáceres, Inmaculada CSIC ORCID | Fecha de publicación: | 2013 | Editor: | Nature Publishing Group | Citación: | Oncogene 32(10): 1274-1283 (2013) | Resumen: | Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines and 25 NSCLC patients with known IGFBP-3 methylation status and response to CDDP. Then, to provide a helpful tool that enables clinicians to identify patients with a potential response to CDDP, we have calculated the association between our diagnostic test and the true outcome of analyzed samples in terms of cisplatin IC 50; the inhibitory concentration that kills 50% of the cell population. Our results suggest that loss of IGFBP-3 expression by promoter methylation in tumor cells treated with CDDP may activate the PI3K/AKT pathway through the specific derepression of IGFIR signaling, inducing resistance to CDDP. This study also provides a predictive test for clinical practice with an accuracy and precision of 0.84 and 0.9, respectively, (P=0.0062). We present a biomarker test that could provide clinicians with a robust tool with which to decide on the use of CDDP, improving patient clinical outcomes. © 2013 Macmillan Publishers Limited. | Descripción: | et al. | URI: | http://hdl.handle.net/10261/77082 | DOI: | 10.1038/onc.2012.146 | Identificadores: | issn: 0950-9232 e-issn: 1476-5594 |
| Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| accesoRestringido.pdf | 15,38 kB | Adobe PDF |  Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
66
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
58
checked on 22-feb-2024
Page view(s)
383
checked on 22-abr-2024
Download(s)
91
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.